Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide and Leuprolide with Radiotherapy in High Risk Prostate Cancer
NCT02508636Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Dec 2015
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of enzalutamide in prostate cancer (PCa), sponsored by University of California, San Francisco. Primary endpoint: Percentage of Participants With Acute Treatment-related Toxicity at 6 months. Started Dec 2015; status: terminated.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02508636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508636.